Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | Director | June 13, 2025 | June 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date June 13, 2025 · Filed June 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 702,840 |
Reported balance
After 2025-06-13 transaction · row 1
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 16,000 · Balance 702,840 F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary date of the grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2035-06-13 | Direct | 95,400 |
Reported balance
After 2025-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-13 · Grant · Acquired 95,400 · Balance 95,400 F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary date of the grant.
F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2025 Filed Jun 17, 2025 01:02 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 95,400 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001437749-25-020568 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires 2035-06-13 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary of the date of the grant. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 01:02 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020568 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,840 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary date of the grant. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:40 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 95,400 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001437749-24-020097 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires 2034-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary of the date of the grant. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:40 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020097 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686,840 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary date of the grant. Read SEC document |
| June 26, 2023 Filed Aug 2, 2023 00:49 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001437749-23-021495 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2033-06-26 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary of the date of the grant. Read SEC document |
| June 26, 2023 Filed Aug 2, 2023 00:49 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-021495 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,840 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:31 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019440 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:31 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019440 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,465 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | OtherCommon Stock Purchase Warrant · Derivative | 181,818 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · derivative · entry 6 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 181,818 shares Expires 2024-04-11 Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 12,700 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · derivative · entry 5 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 12,700 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are fully vested Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · derivative · entry 4 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,000 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are fully vested Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | OtherCommon Stock | 181,818 | $1.10 | $199,999.80 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · nonDerivative · entry 3 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,090 Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon Stock | 12,700 | $0.68 | $8,636.00 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · nonDerivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon Stock | 9,000 | $0.68 | $6,120.00 |
DisclosureSEC source: 0001437749-21-015300 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:26 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 15,097 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001437749-21-015112 · rdgdoc.xml · derivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,097 Underlying: Common stock · 15,097 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date of the 2022 annual meeting of stockholders of the Issuer and June 16, 2022, the first anniversary of the date of the grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:43 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 65,700 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001437749-20-012747 · rdgdoc.xml · derivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,700 Underlying: Common Stock · 65,700 shares Expires 2030-06-07 F1 · derivative.exercise_date: The shares subject to this option shall vest on the first anniversary of the 2020 annual meeting of stockholders of the Issuer. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 12,700 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012101 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2029-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012101 · rdgdoc.xml · derivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:05 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock Warrant · Derivative | 181,818 | $1.10 Strike: $1.10 | $199,999.80 |
DisclosureSEC source: 0001437749-19-007107 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,818 Underlying: Common Stock · 181,818 shares Expires 2024-04-11 F1 · price: Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:05 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 181,818 | $1.10 | $199,999.80 |
DisclosureSEC source: 0001437749-19-007107 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,572 F1 · price: Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Read SEC document |
| September 11, 2018 Filed Feb 6, 2019 21:03 UTC | Vaxart, Inc. VXRT · Entity 6654 | OtherCommon Stock | 34,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007705 · doc4.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,754 F1 · kind: Reflects a pro rata distribution by Life Science Angel Investors II, LLC and LSA Investors Side Fund 2006, LLC to their limited partners. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 21:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 800 | $2.91 | $2,328.00 |
DisclosureSEC source: 0001209191-18-036746 · doc4.xml · nonDerivative · entry 5 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,978 Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 21:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 1,135 | $2.92 | $3,314.20 |
DisclosureSEC source: 0001209191-18-036746 · doc4.xml · nonDerivative · entry 4 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,178 Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 21:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 65 | $2.91 | $189.15 |
DisclosureSEC source: 0001209191-18-036746 · doc4.xml · nonDerivative · entry 3 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,043 Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 21:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 2,000 | $3.46 | $6,920.00 |
DisclosureSEC source: 0001209191-18-036746 · doc4.xml · nonDerivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,978 Read SEC document |
| June 04, 2018 Filed Jun 8, 2018 21:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 1,000 | $4.27 | $4,270.00 |
DisclosureSEC source: 0001209191-18-036746 · doc4.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,978 Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:15 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 228,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010563 · doc4.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,978 F1 · price: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding. Read SEC document |
| February 13, 2018 Filed Feb 6, 2019 21:01 UTC Amendment | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 1,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007704 · doc4a.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,796 F1 · shares: Reflects additional shares not previously included in the reporting person's Form 4, filed with the SEC on February 15, 2018. These shares were also omitted from Form 4 filed by the reporting person with the SEC on June 8, 2018. F2 · price: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.